Hizentra Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Hizentra market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to the rising global prevalence of infections, an increase in health insurance coverage, growing demand for immunoglobulin therapies, expansion of national immunization programs, and the increasing number of medical conferences.

The projected growth for the forecast period is driven by the rising prevalence of autoimmune disorders, an increase in clinical trials, expanding government initiatives, a growing geriatric population, a higher incidence of secondary immunodeficiency diseases, and increasing healthcare expenditure. Key trends for the forecast period include technological advancements, the adoption of subcutaneous immunoglobulin therapies, the rise of digital health technologies, telemedicine, and mobile infusion technologies.

The increasing prevalence of autoimmune disorders is expected to drive the growth of the hizentra market. Autoimmune disorders occur when the immune system mistakenly attacks the body’s healthy cells, tissues, or organs. These disorders are rising due to a mix of genetic, environmental, and lifestyle factors, such as increased exposure to environmental toxins, dietary changes, and reduced pathogen exposure. Hizentra is used to manage autoimmune disorders by providing immunoglobulin replacement therapy, helping regulate immune system activity and alleviating symptoms. For example, a systematic review published in August 2022 by the National Library of Medicine found 928 cases of autoimmune conditions linked to COVID-19 vaccination, with 81.5% of these being newly developed autoimmune diseases. The majority of those affected were women, with a median age of 48 years. As autoimmune disorders continue to rise, the hizentra market is set to expand.

The growth of healthcare expenditure is expected to boost the hizentra market in the future. Healthcare expenditure encompasses the total spending on healthcare services, including prevention, diagnosis, treatment, and management of various health conditions. This spending is increasing due to factors such as an aging population, advancements in medical technology, rising rates of chronic diseases, and higher pharmaceutical and medical service costs. Higher healthcare expenditure enhances the accessibility and affordability of Hizentra, supporting treatment for patients with primary immunodeficiency and other conditions. For instance, according to the U.S. Centers for Medicare & Medicaid Services, healthcare spending in the United States increased by 4.1% in 2022, reaching $4.5 trillion. Spending on clinical and medical services grew by 2.7%, while retail prescription drug spending surged by 8.4% to $405.9 billion. Therefore, the rise in healthcare expenditure is contributing to the market growth of hizentra.

A key trend in the hizentra market is the development of innovative products, such as prefilled syringes, to gain a competitive advantage. Prefilled syringes are single-use devices that come prefilled with a specific dose of medication, ensuring accurate dosing and reducing preparation time. These syringes, typically made of glass or plastic, are designed for ease of use in self-administration or clinical settings. For example, in April 2023, CSL Behring, a U.S.-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had approved a new 50 mL/10 g prefilled syringe for Hizentra (immune globulin subcutaneous [human] 20% Liquid). With this addition, CSL Behring now offers a complete range of prefilled syringe sizes to meet the needs of individuals with primary immunodeficiency (PI) or chronic inflammatory demyelinating polyneuropathy (CIDP). Hizentra is the first immune globulin (Ig) available in a ready-to-administer prefilled syringe format.

The key company operating in the hizentra market is CSL Behring.

North America was the largest region in the hizentra market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hizentra report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the hizentra market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Hizentra is a brand of subcutaneous immunoglobulin (SCIg) therapy used to treat patients with primary immunodeficiencies, such as common variable immunodeficiency (CVID), as well as other immune-related conditions. It contains immunoglobulin G (IgG), a protein that supports the immune system in fighting infections. Hizentra is administered subcutaneously, offering an alternative to intravenous immunoglobulin (IVIg) therapy. It is often preferred for its more flexible dosing schedule and potential for improved convenience compared to traditional IV-based therapies.

The main product types of hizentra include subcutaneous immunoglobulin (SCIg) and intravenous immunoglobulin (IVIg). Subcutaneous immunoglobulin (SCIg) is a form of immunoglobulin therapy given under the skin to help strengthen the immune system in patients with immune deficiencies. It is used for primary immunodeficiency (PI) and chronic inflammatory demyelinating polyneuropathy (CIDP), and is distributed through hospitals, specialty pharmacies, home healthcare providers, and retail pharmacies.

The hizentra market research report is one of a series of new reports that provides hizentra market statistics, including hizentra industry global market size, regional shares, competitors with a hizentra market share, detailed hizentra market segments, market trends and opportunities, and any further data you may need to thrive in the hizentra industry. This hizentra market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hizentra market consists of sales of coagulation factor concentrates, albumin solutions, hyperimmune immunoglobulins, and cryoprecipitate. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.